In a research note issued to investors, Jim Birchenough at BMO Capital Reiterated their Buy rating on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). The analyst placed a $14.00 price target on the stock which indicates a 53.51% upside to the last closing price. In the year following Jim’s ratings, the stocks covered yield an average return of 45.6% according to TipRanks.com. In the past year 72 out of 103 recommendations or 70% were successful.
Wall Street analysts have placed a target price of $9.062 for ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA). This number is based on the mean consensus estimate from the 8 research firms that recently issued reports on the stock.
The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock ranked 2 based on 8 broker recommendations. Of the 8 analysts who have issued estimates, the most bullish sees the stock reaching $11 within the next 12 months while the most conservative sees the stock at $4.5 within the year.
According to analysts, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is expected to report earnings per share for the current fiscal quarter of $-0.28. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.28. The reported number was -0.01 away from the consensus estimate, or a surprise factor of -3.7 .
In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer.